We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Ritter Pharmaceuticals Announces Positive Results from RP-G28 Phase 2 Study

Ritter Pharmaceuticals Announces Positive Results from RP-G28 Phase 2 Study

Ritter Pharmaceuticals Announces Positive Results from RP-G28 Phase 2 Study

Ritter Pharmaceuticals Announces Positive Results from RP-G28 Phase 2 Study

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ritter Pharmaceuticals Announces Positive Results from RP-G28 Phase 2 Study"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ritter Pharmaceuticals, Inc. has announced positive results from its Phase 2 study of RP-G28, the first-in-class treatment of lactose intolerance.

Treatment with RP-G28 was shown to improve digestive symptoms associated with lactose intolerance, including abdominal pain.

Importantly, the reduction of breath hydrogen production after a lactose load was measured, providing evidence of a clinically meaningful biological effect.

This study marks a major milestone in lactose intolerance research, as it represents the first adequate and well-controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.

Subjects in the RP-G28 group reported a reduction in total symptoms of 56 percent after treatment which increased to nearly a 70 percent reduction by 30 days post-treatment.

Importantly, subjects had a statistically significant decrease in abdominal pain (p = 0.03) compared to those receiving placebo.

The reduction in total symptoms was consistent with the improvement in hydrogen breath test results following post-treatment lactose challenge as compared to baseline (pre-treatment) results.

Subjects treated with RP-G28 had a 15 percent greater decrease in hydrogen production as compared to those receiving placebo. RP-G28 was well tolerated with no significant study-drug related adverse events.

Ritter Pharma plans to release the complete data set for the Phase 2 trial at an upcoming major medical meeting or in a peer-reviewed journal.

"We are very pleased with the results of our Phase 2 trial of RP-G28, demonstrating improvements in both lactose digestion and symptoms," stated Andrew Ritter, Ritter Pharma's president and chief executive officer.

Ritter continued, "These data will enable us to advance through late-stage clinical development in order to bring RP-G28 to the many patients suffering from inadequately treated lactose intolerance."

"There are no effective or reliable long-term treatments currently available for those with lactose intolerance," said Dennis Savaiano, Ph.D., professor of Foods and Nutrition and former dean at Purdue University, who is considered one of the world's foremost experts on lactose intolerance.

Savaiano continued, "With these strong results, RP-G28 has great potential to help millions of patients with lactose intolerance consume dairy products again."